Main Street Financial Solutions LLC Makes New Investment in Merck & Co., Inc. $MRK

Main Street Financial Solutions LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 26,862 shares of the company’s stock, valued at approximately $3,452,000.

Other large investors have also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. High Note Wealth LLC grew its holdings in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Down 2.1%

Shares of MRK stock opened at $153.21 on Thursday. The stock has a market cap of $378.00 billion, a price-to-earnings ratio of 122.57, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $156.92. The firm’s 50 day moving average price is $130.39 and its two-hundred day moving average price is $122.04.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 20,784 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Analysts Set New Price Targets

MRK has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. The Goldman Sachs Group increased their target price on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. UBS Group lifted their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Finally, Argus boosted their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $147.60.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.